Drug Compounding Can't Be Justified By Price, FDA Says
Executive Summary
Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.
You may also be interested in...
FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan
FDA wants more companies to adopt continuous manufacturing, which could expand the US manufacturing base.
FDA Backs Off From Early Citations Of Compounder Sterility Issues
A month after compounding pharmacists' latest annual visit to Congress, FDA has acted on one of their chief complaints – investigators citing them for GMP violations even in cases where the agency later acknowledged they were exempt.
Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact
In theory, reviewing generic applications faster should speed competition; in practice, FDA's new policy likely won't make too much difference.